A Multicenter, Single-Arm, Open-Label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 May 2019
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Registrational
- Acronyms STRATUS
- Sponsors Celgene Corporation
- 18 May 2019 This trial has been completed in Ireland .
- 22 Nov 2018 This trial has been completed in Austria.
- 26 Sep 2018 This trial has been discontinued in Estonia.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History